FDA Approves Treosulfan with Fludarabine As a Preparative Regimen for alloHSCT in Adult and Paediatric Patients with AML or MDS By Ogkologos - March 13, 2025 670 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the MC-FludT.14/L Trial II Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Aumolertinib FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA2-mutated Metastatic Castration-Sensitive Prostate Cancer The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration MOST POPULAR Sotorasib Shows Increase in PFS and a More Favourable Safety Compared... February 21, 2023 Evidence for the Utility of ctDNA Monitoring for Recurrence After CRC... October 3, 2024 ASCO 2021 news: follow-up treatments pave the way June 9, 2021 A Combination of Avutometinib Plus Defactinib Results in Clinically Meaningful Benefit... August 5, 2025 Load more HOT NEWS Dr. Catherine Hamlin, Pioneer In Fistula Surgery, Passes Away At Age... Survivorship and Immune Checkpoint Inhibitors Immunotherapy Drug with Two Targets Shows Promise against HPV-Related Cancers The Most Successful Female Singer Of The 1970s Disappeared. Now She’s...
